Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
Fabrizio Cantini(Ospedale di Prato Santo Stefano), Delia Goletti(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani)
Cited by 179
Related Papers
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
|Journal of Infection|2020|445
Optimization of the autophagy measurement in a human cell line and primary cells by flow cytometry
|European Journal of Histochemistry|2019|11